Phenominer Database Results (130 results)

 
 
How to display a graph
Strain Phenotype Conditions Study Experiment Name Sex Age # of Animals Value Units SEM SD Method Method Site Method Duration Post Insult Type Post Insult Time Value Post Insult Time Unit Method Notes Clinical Measurement Notes Record ID Study ID
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 17 3.3 ml/min/100g 0.11 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99992 2378
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 3.9 ml/min 0.2 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100600 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.32 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100605 2479
MWF/ZtmRrrc renal filtration fraction control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. glomerular filtration trait male 126 days 7 0.19 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100943 2541
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 3.95 ml/min 0.7 1.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100465 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 5.45 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100471 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100472 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 22 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 5 0.09 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100474 2479
WKY single nephron filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 snff 100522 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 24.0 x 10E10 dyne x s/cm5 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pe 100546 2479
WKY glomerular transcapillary hydraulic pressure gradient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 35.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 dp 100547 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 48.0 mmHg 2.0 6.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 dp 100550 2479
WKY afferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.68 x 10E10 dyne x s/cm5 0.14 0.4 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 ra 100554 2479
SD renal filtration fraction control condition Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.3 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 GFR by inulin method 99913 2358
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 8 2.32 ml/min/100g 0.11 0.31 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99953 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 7 10.0 mmHg/ml/min 0.6 1.59 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99960 2378
WKY afferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.04 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ra 100556 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 0.84 x 10E10 dyne x s/cm5 0.1 0.24 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days re 100558 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 0.82 x 10E10 dyne x s/cm5 0.08 0.23 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 re 100559 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.54 x 10E10 dyne x s/cm5 0.12 0.36 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 re 100560 2479
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 22.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 109968 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.13 x 10E10 dyne x s/cm5 0.12 0.36 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 re 100557 2479
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 11 6.3 mmHg/ml/min 0.4 1.33 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99995 2378
SD renal plasma flow to body weight ratio control condition Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. kidney plasma flow trait male 420 days-450 days 9 1.0 ml/min/100g 0.06 0.18 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 101231 2582
WKY mean proximal tubular hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 14.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 pt 100539 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 21.0 x 10E10 dyne x s/cm5 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pe 100543 2479
WKY glomerular transcapillary hydraulic pressure gradient puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 35.0 mmHg 3.0 7.35 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days dp 100548 2479
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 8 2.33 ml/min/100g 0.09 0.25 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99952 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 8 9.0 mmHg/ml/min 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99961 2378
MWF/ZtmRrrc renal plasma flow to body weight ratio control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 126 days 7 2.44 ml/min/100g 0.28 0.73 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100939 2541
WKY afferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 18.0 mmHg 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 pia 100579 2479
WKY efferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 29.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 pie 100582 2479
WKY efferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 31.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 pie 100584 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.29 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100606 2479
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 16 3.19 ml/min/100g 0.13 0.52 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99994 2378
SD renal plasma flow control condition Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. kidney plasma flow trait male 90 days 9 3.83 ml/min 0.21 0.63 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 101228 2582
MWF/ZtmRrrc renal plasma flow (PAH) enalapril (50 mg/l) (for 182 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 246 days 6 7.6 ml/min 0.33 0.8 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100938 2541
MWF/ZtmRrrc renal filtration fraction enalapril (50 mg/l) (for 182 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. glomerular filtration trait male 246 days 6 0.3 null 0.02 0.04 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100946 2541
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 6 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days snff 100523 2479
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 2.43 x 10E10 dyne x s/cm5 0.28 0.69 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days rt 100563 2479
WKY total arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 3.03 x 10E10 dyne x s/cm5 0.22 0.66 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 rt 100565 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 15.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 100538 2479
WKY glomerular transcapillary hydraulic pressure gradient 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 33.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 dp 100549 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.27 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100479 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 4.5 ml/min 0.21 0.63 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100463 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.32 null 0.03 0.09 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100478 2479
MWF/Ztm renal filtration fraction arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. glomerular filtration trait male 126 days-147 days 8 0.32 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 109247 3138
WKY efferent arteriolar hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 21.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days pt 109966 2479
WKY total arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 1.53 x 10E10 dyne x s/cm5 0.12 0.34 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 rt 100566 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 12.0 mmHg 0.3 0.73 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days pia 100578 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 6 14.0 mmHg 1.0 2.45 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 15 days pie 100583 2479
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 17 6.6 mmHg/ml/min 0.3 1.24 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99997 2378
MWF/ZtmRrrc renal plasma flow to body weight ratio control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 246 days 8 1.72 ml/min/100g 0.07 0.19 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100941 2541
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 7 2.16 ml/min/100g 0.18 0.48 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99950 2378
WKY afferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 18.0 mmHg 0.3 0.85 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 pia 100581 2479
WKY efferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 33.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pie 100585 2479
WKY efferent colloid osmotic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 29.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pie 100586 2479
SD effective renal plasma flow streptozotocin (60 mg/kg) then insulin Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.28 ml/min/100g 0.05 0.15 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 154 days 99905 2358
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.32 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100604 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.28 null 0.03 0.09 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100607 2479
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 17 16.7 mmHg/ml/min 1.4 5.77 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99996 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 16 7.1 mmHg/ml/min 0.3 1.2 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99998 2378
SD renal plasma flow control condition Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. kidney plasma flow trait male 420 days-450 days 9 5.73 ml/min 0.41 1.23 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 101229 2582
MWF/ZtmRrrc renal plasma flow to body weight ratio enalapril (50 mg/l) (for 182 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 246 days 6 1.71 ml/min/100g 0.09 0.23 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100942 2541
WKY mean proximal tubular hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 14.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 pt 100537 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 17.0 x 10E10 dyne x s/cm5 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 pe 100544 2479
WKY glomerular transcapillary hydraulic pressure gradient controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 31.0 mmHg 2.0 5.66 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 dp 100551 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.49 x 10E10 dyne x s/cm5 0.11 0.33 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ra 100555 2479
SD renal filtration fraction streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.29 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 154 days GFR by inulin method 99912 2358
SD renal filtration fraction streptozotocin (60 mg/kg) then insulin Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.29 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 224 days GFR by inulin method 99932 2358
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 8 3.09 ml/min/100g 0.18 0.51 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99951 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 8 8.8 mmHg/ml/min 0.5 1.41 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99962 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 6 8.8 mmHg/ml/min 0.5 1.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99964 2378
WKY single nephron filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.28 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 snff 100524 2479
MWF/Ztm renal filtration fraction arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. glomerular filtration trait male 112 days-147 days 8 0.35 null 0.02 0.05 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 109246 3138
WKY efferent arteriolar hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 17.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 pt 109967 2479
WKY efferent arteriolar hydraulic pressure enalapril (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 24.0 mmHg 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 109969 2479
WKY efferent arteriolar resistance controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 0.5 x 10E10 dyne x s/cm5 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 re 100561 2479
WKY renal plasma flow (PAH) controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.15 ml/min 0.32 0.91 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100468 2479
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 16 3.15 ml/min/100g 0.13 0.52 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99993 2378
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then 0.9% sodium chloride solution (for 0.5 hours) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.37 ml/min 0.24 0.54 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100603 2479
SD effective renal plasma flow streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.31 ml/min/100g 0.06 0.16 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 154 days 99906 2358
WKY single nephron filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.31 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 snff 100525 2479
WKY afferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 1.74 x 10E10 dyne x s/cm5 0.18 0.54 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 ra 100552 2479
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) and bosentan (100 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 6 2.42 ml/min/100g 0.09 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99954 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 14 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 8 9.2 mmHg/ml/min 0.4 1.13 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 28 days 99963 2378
WKY afferent colloid osmotic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 18.1 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 pia 100577 2479
WKY afferent colloid osmotic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 18.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 0 ce 100580 2479
SD effective renal plasma flow control condition Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.24 ml/min/100g 0.06 0.18 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 99907 2358
MWF/ZtmRrrc renal plasma flow (PAH) enalapril (50 mg/l) (for 60 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 126 days 8 10.6 ml/min 0.57 1.6 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100936 2541
MWF/ZtmRrrc renal filtration fraction control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. glomerular filtration trait male 246 days 8 0.27 null 0.01 0.04 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100945 2541
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 3.79 ml/min 0.19 0.57 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100467 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 9 4.99 ml/min 0.5 1.5 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100469 2479
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.34 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100476 2479
WKY mean proximal tubular hydraulic pressure puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 19.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 100540 2479
WKY efferent arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 18.0 x 10E10 dyne x s/cm5 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 0 pe 100542 2479
SD renal filtration fraction streptozotocin (60 mg/kg) then insulin Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.3 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 154 days GFR by inulin method 99911 2358
SD effective renal plasma flow streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.27 ml/min/100g 0.06 0.18 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 224 days 99930 2358
SD renal filtration fraction streptozotocin (60 mg/kg) then insulin then Moexipril (30-35 mg/kg/d) (for 112 days) Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.29 null 0.01 0.02 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 224 days GFR by inulin method 99933 2358
WKY total arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 8 2.49 x 10E10 dyne x s/cm5 0.21 0.59 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 rt 100564 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 497 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 9 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100480 2479
MWF/Ztm renal plasma flow (PAH) arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. kidney plasma flow trait male 112 days-147 days 8 3.39 ml/min 0.34 0.96 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 109239 3138
MWF/Ztm renal plasma flow (PAH) arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. kidney plasma flow trait male 126 days-147 days 8 1.78 ml/min 0.17 0.47 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 109240 3138
MWF/Ztm ratio of renal plasma flow to kidney weight (PAH) arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. kidney plasma flow trait male 112 days-147 days 8 2.52 ml/min/g 0.18 0.51 p-aminohippurate analysis by liquid phase colorimetry left kidney 0.0 0 109244 3138
MWF/Ztm ratio of renal plasma flow to kidney weight (PAH) arterial catheter implantation and controlled hemorrhage Remuzzi A, etal., Kidney Int. 1988 Oct;34(4):481-6. doi: 10.1038/ki.1988.206. kidney plasma flow trait male 126 days-147 days 8 2.05 ml/min/g 0.14 0.39 p-aminohippurate analysis by liquid phase colorimetry left kidney 0.0 0 109245 3138
WKY renal filtration fraction puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 7 0.09 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100473 2479
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 17 1.72 ml/min/100g 0.11 0.45 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99991 2378
WKY renal vascular resistance unilateral nephrectomy (for 28 days) then streptozotocin (35 mg/kg) then enalapril (10 mg/kg/d) (for 154 days) and bosentan (100 mg/kg/d) (for 154 days) Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. arterial blood pressure trait male 0 days 16 6.8 mmHg/ml/min 0.3 1.2 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99999 2378
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) then saralasin (0.3 mg/kg/hr) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.6 ml/min 0.1 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100601 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 5 4.36 ml/min 0.36 0.8 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100602 2479
SD renal plasma flow to body weight ratio control condition Jung FF, etal., J Am Soc Nephrol. 1995 Feb;5(8):1573-80. kidney plasma flow trait male 90 days 9 0.97 ml/min/100g 0.05 0.15 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 101230 2582
WKY renal plasma flow to body weight ratio unilateral nephrectomy (for 28 days) then vehicle control condition Ding SS, et al., J Cardiovasc Pharmacol. 2003 Jul;42(1):48-54. kidney plasma flow trait male 0 days 11 2.28 ml/min/100g 0.07 0.23 p-aminohippurate analysis by liquid phase colorimetry 0.0 unx 168 days 99990 2378
MWF/ZtmRrrc renal plasma flow (PAH) control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 126 days 7 9.4 ml/min 1.02 2.7 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100935 2541
MWF/ZtmRrrc renal plasma flow (PAH) control condition Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 246 days 8 7.4 ml/min 0.28 0.8 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100937 2541
MWF/ZtmRrrc renal plasma flow to body weight ratio enalapril (50 mg/l) (for 60 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. kidney plasma flow trait male 126 days 8 2.84 ml/min/100g 0.14 0.39 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100940 2541
WKY total arteriolar resistance 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 2.87 x 10E10 dyne x s/cm5 0.28 0.84 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 0 rt 100562 2479
WKY renal plasma flow (PAH) 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.65 ml/min 0.55 1.56 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100466 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 8 4.18 ml/min 0.47 1.33 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 490 days 100470 2479
WKY renal filtration fraction 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.26 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100475 2479
WKY single nephron filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.26 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100526 2479
WKY mean proximal tubular hydraulic pressure controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 8 16.0 mmHg 1.0 2.83 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 pt 100541 2479
WKY efferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 9 22.0 x 10E10 dyne x s/cm5 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry renal efferent arteriole 0.0 PA IV 50mg/kg 0 pe 100545 2479
WKY afferent arteriolar resistance puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney blood vessel physiology trait male 0 days 6 1.6 x 10E10 dyne x s/cm5 0.22 0.54 p-aminohippurate analysis by liquid phase colorimetry renal afferent arteriole 0.0 PA IV 50mg/kg 15 days ra 100553 2479
SD effective renal plasma flow streptozotocin (60 mg/kg) then insulin Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.31 ml/min/100g 0.08 0.22 p-aminohippurate analysis by liquid phase colorimetry 0.0 stz 224 days 99929 2358
SD effective renal plasma flow control condition Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. kidney plasma flow trait male 0 days 8 2.33 ml/min/100g 0.07 0.2 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 99931 2358
SD renal filtration fraction control condition Perico N, et al., J Am Soc Nephrol. 1994 Oct;5(4):1139-46. glomerular filtration trait male 0 days 8 0.29 null 0.0 0.01 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 GFR by inulin method 99934 2358
WKY efferent arteriolar hydraulic pressure 0.9% sodium chloride solution (3 ml) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. blood molecular composition trait male 0 days 9 18.0 mmHg 1.0 3.0 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 pt 109965 2479
WKY renal plasma flow (PAH) puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. kidney plasma flow trait male 0 days 7 3.66 ml/min 0.62 1.64 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 15 days 100464 2479
WKY renal filtration fraction controlled enalapril content drinking water (50 mg/l) (for 7 days) then puromycin aminonucleoside (50 mg/kg) Anderson S, et al., J Clin Invest. 1988 Nov;82(5):1757-68. glomerular filtration trait male 0 days 8 0.28 null 0.01 0.03 p-aminohippurate analysis by liquid phase colorimetry 0.0 PA IV 50mg/kg 0 100477 2479
MWF/ZtmRrrc renal filtration fraction enalapril (50 mg/l) (for 60 days) Remuzzi A, et al., J Clin Invest. 1990 Feb;85(2):541-9. glomerular filtration trait male 126 days 8 0.21 null 0.02 0.06 p-aminohippurate analysis by liquid phase colorimetry 0.0 0 100944 2541